Showing 3581-3590 of 5846 results for "".
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease
- Hair Care Market to Reach $20B by 2029: Reporthttps://practicaldermatology.com/news/hair-care-market-reach-20b-2029-report/2470831/The U.S. hair care market is projected to reach $20 billion by 2029, according to a report released by ResearchAndMarkets.com. The report noted that hair care remains resilient despite economic fluctuations due to consumer demand for premium and sustainable products and cited the rising p
- Study: Head and Neck Melanomas Show Unique Patternshttps://practicaldermatology.com/news/study-head-and-neck-melanomas-show-unique-patterns/2470807/A recent study published in the Journal of the American Academy of Dermatology reports that cutaneous melanomas located on the head and neck (CHNM) exhibit distinct clinicopathological features and treatment outcomes compared to melanomas at other anatomical sites (CMOS). Researc
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://practicaldermatology.com/news/report-regenerative-aesthetics-exosome-market-poised-355-cagr-through-2031/2470805/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin rejuvenation, hair restoration, scar redu
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- Study: Ongoing Inequities in Dermatology Productivity Metricshttps://practicaldermatology.com/news/study-ongoing-inequities-dermatology-productivity-metrics/2470777/A new study in JAMA Dermatology revealed that while the 2021 Medicare physician fee schedule updates reduced inequities in work relative value units (wRVUs) for outpatient dermatology visits, significant disparities based on patient demographics persist. Analyzing data from 89,656
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- Study Explores How Moderate to Severe Hand Eczema Affects Quality of Lifehttps://practicaldermatology.com/news/moderate-severe-hand-eczema-quality-life-challenges-explored/2470762/Even mild hand eczema can significantly impair one's quality of life and mental health, according to a new study. The findings, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, spanned data collected from 2013 to 2020, addressed the outsized impact of hand eczem
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate